Found: 26
Select item for more details and to access through your institution.
Personalized Diagnosis and Therapy for Multiple Sclerosis.
- Published in:
- Journal of Personalized Medicine, 2022, v. 12, n. 6, p. 1017, doi. 10.3390/jpm12061017
- By:
- Publication type:
- Article
Recommendations for the Diagnosis and Treatment of Multiple Sclerosis Relapses.
- Published in:
- Journal of Personalized Medicine, 2022, v. 12, n. 1, p. 6, doi. 10.3390/jpm12010006
- By:
- Publication type:
- Article
Assessing Blood-Based Biomarkers to Define a Therapeutic Window for Natalizumab.
- Published in:
- Journal of Personalized Medicine, 2021, v. 11, n. 12, p. 1347, doi. 10.3390/jpm11121347
- By:
- Publication type:
- Article
Single‐cell multi‐omics analysis of COVID‐19 patients with pre‐existing autoimmune diseases shows aberrant immune responses to infection.
- Published in:
- European Journal of Immunology, 2024, v. 54, n. 1, p. 1, doi. 10.1002/eji.202350633
- By:
- Publication type:
- Article
Stable antigen-specific T-cell hyporesponsiveness induced by tolerogenic dendritic cells from multiple sclerosis patients.
- Published in:
- European Journal of Immunology, 2012, v. 42, n. 3, p. 771, doi. 10.1002/eji.201141835
- By:
- Publication type:
- Article
Optimal response to dimethyl fumarate is mediated by a reduction of Th1‐like Th17 cells after 3 months of treatment.
- Published in:
- CNS Neuroscience & Therapeutics, 2019, v. 25, n. 9, p. 995, doi. 10.1111/cns.13142
- By:
- Publication type:
- Article
Predicting therapeutic response to fingolimod treatment in multiple sclerosis patients.
- Published in:
- CNS Neuroscience & Therapeutics, 2018, v. 24, n. 12, p. 1175, doi. 10.1111/cns.12851
- By:
- Publication type:
- Article
Epstein-Barr Virus and Multiple Sclerosis: A Convoluted Interaction and the Opportunity to Unravel Predictive Biomarkers.
- Published in:
- International Journal of Molecular Sciences, 2023, v. 24, n. 8, p. 7407, doi. 10.3390/ijms24087407
- By:
- Publication type:
- Article
Baseline Differences in Minor Lymphocyte Subpopulations may Predict Response to Fingolimod in Relapsing-Remitting Multiple Sclerosis Patients.
- Published in:
- CNS Neuroscience & Therapeutics, 2016, v. 22, n. 7, p. 584, doi. 10.1111/cns.12548
- By:
- Publication type:
- Article
Beneficial Effect of Tolerogenic Dendritic Cells Pulsed with MOG Autoantigen in Experimental Autoimmune Encephalomyelitis.
- Published in:
- CNS Neuroscience & Therapeutics, 2015, v. 21, n. 3, p. 222, doi. 10.1111/cns.12342
- By:
- Publication type:
- Article
Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates.
- Published in:
- Multiple Sclerosis Journal, 2018, v. 24, n. 14, p. 1843, doi. 10.1177/1352458517735191
- By:
- Publication type:
- Article
Baseline clinical status as a predictor of methylprednisolone response in multiple sclerosis relapses.
- Published in:
- Multiple Sclerosis Journal, 2016, v. 22, n. 1, p. 117, doi. 10.1177/1352458515590648
- By:
- Publication type:
- Article
Regulatory role of vitamin D in T-cell reactivity against myelin peptides in relapsing-remitting multiple sclerosis patients.
- Published in:
- BMC Neurology, 2012, v. 12, n. 1, p. 103, doi. 10.1186/1471-2377-12-103
- By:
- Publication type:
- Article
Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies: A Multi-Centre Study.
- Published in:
- Journal of Clinical Medicine, 2023, v. 12, n. 23, p. 7243, doi. 10.3390/jcm12237243
- By:
- Publication type:
- Article
Seroprevalence of SARS-CoV-2 in a Cohort of Patients with Multiple Sclerosis under Disease-Modifying Therapies.
- Published in:
- Journal of Clinical Medicine, 2022, v. 11, n. 9, p. 2509, doi. 10.3390/jcm11092509
- By:
- Publication type:
- Article
MAP7 and MUCL1 Are Biomarkers of Vitamin D3-Induced Tolerogenic Dendritic Cells in Multiple Sclerosis Patients.
- Published in:
- Frontiers in Immunology, 2019, p. N.PAG, doi. 10.3389/fimmu.2019.01251
- By:
- Publication type:
- Article
Monitoring CD49d Receptor Occupancy: A Method to Optimize and Personalize Natalizumab Therapy in Multiple Sclerosis Patients.
- Published in:
- Cytometry. Part B, 2018, v. 94, n. 2, p. 327, doi. 10.1002/cyto.b.21527
- By:
- Publication type:
- Article
Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis.
- Published in:
- JAMA Neurology, 2018, v. 75, n. 11, p. 1407, doi. 10.1001/jamaneurol.2018.2109
- By:
- Publication type:
- Article
Th1Th17<sub>CM</sub> Lymphocyte Subpopulation as a Predictive Biomarker of Disease Activity in Multiple Sclerosis Patients under Dimethyl Fumarate or Fingolimod Treatment.
- Published in:
- Mediators of Inflammation, 2019, p. 1, doi. 10.1155/2019/8147803
- By:
- Publication type:
- Article
Vitamin D3-Induced Tolerogenic Dendritic Cells Modulate the Transcriptomic Profile of T CD4<sup>+</sup> Cells Towards a Functional Hyporesponsiveness.
- Published in:
- Frontiers in Immunology, 2021, v. 11, p. N.PAG, doi. 10.3389/fimmu.2020.599623
- By:
- Publication type:
- Article
Tolerogenic dendritic cells in experimental autoimmune encephalomyelitis, specific tolerance induction?
- Published in:
- 2012
- By:
- Publication type:
- Abstract
Characterization of recent thymic emigrants (RTEs), transitional B and Th17 cells in multiple sclerosis (MS).
- Published in:
- 2011
- By:
- Publication type:
- Abstract
Combined Therapy of Vitamin D3-Tolerogenic Dendritic Cells and Interferon-β in a Preclinical Model of Multiple Sclerosis.
- Published in:
- Biomedicines, 2021, v. 9, n. 12, p. 1758, doi. 10.3390/biomedicines9121758
- By:
- Publication type:
- Article
Cryopreserved vitamin D3-tolerogenic dendritic cells pulsed with autoantigens as a potential therapy for multiple sclerosis patients.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Comparative transcriptomic profile of tolerogenic dendritic cells differentiated with vitamin D3, dexamethasone and rapamycin.
- Published in:
- Scientific Reports, 2018, v. 8, n. 1, p. 1, doi. 10.1038/s41598-018-33248-7
- By:
- Publication type:
- Article
Case report: tumefactive demyelinating lesions after the second cycle of alemtuzumab in multiple sclerosis; immune cell profile and biomarkers.
- Published in:
- Frontiers in Immunology, 2024, p. 1, doi. 10.3389/fimmu.2024.1395749
- By:
- Publication type:
- Article